Aleniglipron

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

8mo

GPCRPhase 2$4.3B

Aleniglipron Phase 2 Results Expected

Aleniglipron• Obesity, Overweight, or Chronic Weight Management50

Oct 15Estimated

00%

5mo

GPCRPhase 2$4.3B

Aleniglipron Phase 2 Results Expected

Aleniglipron• Obesity, Overweight, or Chronic Weight Management220

Jul 15Estimated

00%

Competitive Landscape

0 competitors in Obesity, Overweight, or Chronic Weight Management

Drug Information

Target Indication

Obesity, Overweight, or Chronic Weight Management

Clinical Trial

Last updated: 1/12/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

GPCR

Structure Therapeutics Inc.

Related Pipeline

Overweight or Obesity